Thr479

Site Information
EGsQGELtPANsQsR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 449348
Available spectra: 11 CST
Associated spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 4 , 5 , 6 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 ) , mutation of modification site ( 4 ) , phospho-antibody ( 4 ) , western blotting ( 4 )
Disease tissue studied:	brain cancer ( 87 ) , glioblastoma ( 87 ) , glioma ( 87 ) , breast cancer ( 8 , 32 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , cervical cancer ( 4 , 66 ) , cervical adenocarcinoma ( 4 , 66 ) , gastric cancer ( 29 ) , leukemia ( 39 , 83 , 84 ) , acute myelogenous leukemia ( 39 ) , chronic myelogenous leukemia ( 83 , 84 ) , lung cancer ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 32 , 46 ) , non-small cell lung cancer ( 13 , 14 , 15 , 17 , 18 , 19 , 24 , 25 , 26 , 27 , 30 , 31 , 32 ) , non-small cell lung adenocarcinoma ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 25 , 27 , 46 ) , non-small cell large cell lung carcinoma ( 14 , 17 ) , non-small cell squamous cell lung carcinoma ( 16 , 31 ) , small-cell lung cancer ( 11 , 12 ) , pancreatic ductal adenocarcinoma ( 10 ) , melanoma skin cancer ( 5 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 10 ) , 'stem, embryonic' ( 69 ) , 293 (epithelial) [AT1 (human), transfection] ( 60 ) , 293 (epithelial) ( 70 ) , 293E (epithelial) ( 45 ) , A549 (pulmonary) ( 13 , 21 ) , breast ( 2 ) , BT-20 (breast cell) ( 32 ) , BT-549 (breast cell) ( 32 ) , Cal-12T (pulmonary) ( 19 ) , Calu-3 (pulmonary) ( 15 ) , DMS153 (pulmonary) ( 18 ) , DMS53 (pulmonary) ( 12 ) , DMS79 (pulmonary) ( 11 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 33 ) , Flp-In T-Rex-293 (epithelial) ( 33 ) , HCC15 (pulmonary) ( 16 ) , HCC44 (pulmonary) ( 19 ) , HCC78 (pulmonary) ( 17 ) , HCC827 (pulmonary) ( 15 ) , HEK293T (epithelial) ( 89 ) , HeLa (cervical) ( 6 , 28 , 44 , 47 , 48 , 49 , 50 , 59 , 72 , 73 , 74 , 78 , 79 , 80 , 81 , 82 , 94 ) , HeLa S3 (cervical) ( 4 , 66 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 8 ) , HMLER ('stem, breast cancer') ( 8 ) , HUES-7 ('stem, embryonic') ( 68 ) , HUES-9 ('stem, embryonic') ( 58 ) , Jurkat (T lymphocyte) ( 22 , 35 , 36 , 37 , 38 , 40 , 41 , 42 , 43 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 61 , 62 , 63 , 64 , 65 , 71 , 75 , 76 , 77 , 85 , 86 , 88 , 90 , 91 , 92 , 93 ) , K562 (erythroid) ( 28 , 67 , 83 , 84 ) , KG-1 (myeloid) ( 39 ) , liver ( 9 ) , LOU-NH91 (squamous) ( 16 , 32 ) , lung ( 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ) , M059J (glial) ( 98 ) , M059K (glial) ( 87 , 95 , 96 , 97 ) , MDA-MB-231 (breast cell) ( 32 ) , MDA-MB-468 (breast cell) ( 32 ) , MKN-45 (gastric) ( 29 ) , NCI-H128 (pulmonary) ( 11 ) , NCI-H1299 (pulmonary) ( 14 ) , NCI-H1355 (pulmonary) ( 13 ) , NCI-H1417 (pulmonary) ( 11 ) , NCI-H1437 (pulmonary) ( 18 , 19 ) , NCI-H1650 (pulmonary) ( 15 ) , NCI-H1666 (pulmonary) ( 19 ) , NCI-H1703 (squamous) ( 16 , 31 ) , NCI-H1734 (pulmonary) ( 14 ) , NCI-H1781 (pulmonary) ( 17 ) , NCI-H1792 (pulmonary) ( 13 ) , NCI-H1944 (pulmonary) ( 14 ) , NCI-H1975 (pulmonary) ( 15 ) , NCI-H2073 (pulmonary) ( 16 , 18 ) , NCI-H209 (pulmonary) ( 11 , 18 ) , NCI-H2106 (pulmonary) ( 15 ) , NCI-H2228 (pulmonary) ( 17 , 25 , 27 ) , NCI-H23 (pulmonary) ( 13 ) , NCI-H2342 (pulmonary) ( 16 ) , NCI-H2405 (pulmonary) ( 19 ) , NCI-H3122 (pulmonary) ( 17 , 24 , 26 ) , NCI-H3255 (pulmonary) ( 30 ) , NCI-H358 (pulmonary) ( 14 ) , NCI-H441 (pulmonary) ( 13 ) , NCI-H446 (pulmonary) ( 12 ) , NCI-H460 (pulmonary) ( 14 , 32 ) , NCI-H520 (squamous) ( 32 ) , NCI-H524 (pulmonary) ( 11 ) , NCI-H526 (pulmonary) ( 12 ) , NCI-H661 (pulmonary) ( 17 ) , NCI-H69 (pulmonary) ( 12 ) , NCI-H82 (pulmonary) ( 12 ) , NCI-H838 (pulmonary) ( 18 ) , PC9 (pulmonary) ( 32 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 46 ) , U-1810 (pulmonary) ( 46 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 5 )

Upstream Regulation
Treatments:	ionizing_radiation ( 89 ) , nocodazole ( 66 ) , UV ( 4 , 87 , 89 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
4	Dubois EL, et al. (2016) UV-dependent phosphorylation of COP9/signalosome in UV-induced apoptosis. Oncol Rep 35, 3101-5 26986008 Curated Info
5	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
6	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
7	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
8	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
9	Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62 24275569 Curated Info
10	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
11	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
12	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
13	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
14	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
15	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
16	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
17	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
18	Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
19	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
20	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
21	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
22	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
23	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
24	Rikova K (2013) CST Curation Set: 18531; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS/T) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759 Curated Info
25	Rikova K (2013) CST Curation Set: 18529; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST], LXRXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXXS/T) (110B7E) Rabbit mAb Cat#: 9614 Phospho-AMPK Substrate Motif [LXRXX(pS/pT) MultiMab(TM) Rabbit mAb mix Cat#: 5759 Curated Info
26	Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
27	Rikova K (2013) CST Curation Set: 18502; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
28	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
29	Rikova K (2012) CST Curation Set: 16145; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
30	Rikova K (2012) CST Curation Set: 16146; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
31	Rikova K (2012) CST Curation Set: 16147; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966 Curated Info
32	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
33	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
34	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
35	Mulhern D (2012) CST Curation Set: 14049; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
36	Mulhern D (2012) CST Curation Set: 14050; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (SQ) Immunoaffinity Beads Cat#: 9884 Curated Info
37	Mulhern D (2012) CST Curation Set: 14051; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
38	Mulhern D (2012) CST Curation Set: 14052; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
39	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
40	Mulhern D (2011) CST Curation Set: 13261; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939 Curated Info
41	Mulhern D (2011) CST Curation Set: 13262; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939 Curated Info
42	Mulhern D (2011) CST Curation Set: 13263; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: ATM/ATR substrate (s/t)QG Cat#: 6939 Curated Info
43	Mulhern D (2011) CST Curation Set: 13265; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
44	Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540 21857030 Curated Info
45	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info
46	Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78 21413766 Curated Info
47	Zhou J (2011) CST Curation Set: 11707; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
48	Zhou J (2011) CST Curation Set: 11708; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate (S/TQG) (P-S/T2-100) Rabbit mAb Cat#: 6966, PTMScan(R) Phospho-ATM/ATR Substrate Motif (S/TQG) Immunoaffinity Beads Cat#: 6969 Curated Info
49	Zhou J (2011) CST Curation Set: 11709; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (SQ) Immunoaffinity Beads Cat#: 9884 Curated Info
50	Zhou J (2011) CST Curation Set: 11710; Year: 2011; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (SQ) Immunoaffinity Beads Cat#: 9884 Curated Info
51	Guo A (2011) CST Curation Set: 11523; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (SQ) Immunoaffinity Beads Cat#: 9884 Curated Info
52	Guo A (2011) CST Curation Set: 11524; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (SQ) (D23H2/D69H5) Rabbit mAb Cat#: 9607, PTMScan(R) Phospho-ATM/ATR Substrate (SQ) Immunoaffinity Beads Cat#: 9884 Curated Info
53	Guo A (2011) CST Curation Set: 11375; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
54	Guo A (2011) CST Curation Set: 11379; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
55	Guo A (2011) CST Curation Set: 11380; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
56	Guo A (2011) CST Curation Set: 11384; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
57	Guo A (2011) CST Curation Set: 11115; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
58	Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3 21406692 Curated Info
59	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
60	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
61	Possemato A (2010) CST Curation Set: 10274; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (G/N/L)p[ST] Curated Info
62	Possemato A (2010) CST Curation Set: 10303; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
63	Possemato A (2010) CST Curation Set: 9960; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
64	Possemato A (2010) CST Curation Set: 8970; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
65	Possemato A (2010) CST Curation Set: 9157; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Curated Info
66	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
67	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
68	Van Hoof D, et al. (2009) Phosphorylation dynamics during early differentiation of human embryonic stem cells. Cell Stem Cell 5, 214-26 19664995 Curated Info
69	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
70	Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501 19413330 Curated Info
71	Possemato A (2009) CST Curation Set: 6850; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
72	Zhou J (2009) CST Curation Set: 6246; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
73	Zhou J (2009) CST Curation Set: 6247; Year: 2009; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
74	Zhou J (2009) CST Curation Set: 6241; Year: 2009; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
75	Zhou J (2009) CST Curation Set: 6048; Year: 2009; Biosample/Treatment: cell line, Jurkat/untreated; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
76	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
77	Possemato A (2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Curated Info
78	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
79	Zhou J (2008) CST Curation Set: 4842; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993 Curated Info
80	Zhou J (2008) CST Curation Set: 4777; Year: 2008; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993 Curated Info
81	Zhou J (2008) CST Curation Set: 4778; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993 Curated Info
82	Zhou J (2008) CST Curation Set: 4707; Year: 2008; Biosample/Treatment: cell line, HeLa/UV; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) ATM/ATR Substrate Antibody (polyAB) Cat#: 3005, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQ) Immunoaffinity Beads Cat#: 1980 Curated Info
83	Stokes M (2008) CST Curation Set: 4392; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
84	Stokes M (2008) CST Curation Set: 4393; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
85	Stokes M (2008) CST Curation Set: 3881; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
86	Stokes M (2008) CST Curation Set: 3885; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
87	Stokes MP, et al. (2007) Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A 104, 19855-60 18077418 Curated Info
88	Possemato A (2007) CST Curation Set: 3481; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996 Curated Info
89	Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6 17525332 Curated Info
90	Possemato A (2007) CST Curation Set: 2795; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
91	Possemato A (2007) CST Curation Set: 2796; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate Motif (pS/pTQG) Antibody Cat#: 5074, PTMScan(R) Phospho-ATM/ATR Substrate Motif (pS/pTQG) Immunoaffinity Beads Cat#: 1993 Curated Info
92	Possemato A (2007) CST Curation Set: 2797; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
93	Possemato A (2007) CST Curation Set: 2798; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Curated Info
94	Beausoleil SA, et al. (2006) A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol 24, 1285-92 16964243 Curated Info
95	Stokes M (2006) CST Curation Set: 1616; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
96	Stokes M (2006) CST Curation Set: 1617; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
97	Stokes M (2006) CST Curation Set: 1123; Year: 2006; Biosample/Treatment: cell line, M059K/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info
98	Stokes M (2005) CST Curation Set: 910; Year: 2005; Biosample/Treatment: cell line, M059J/UV; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info